Toggle menu

NOVEL Study

Start date:
April 2019
End date:
April 2021
Co-ordinated by:
LumiraDx
Main trial site:
Royal Infirmary Edinburgh

Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.

Primary Objective: evaluation of diagnostic platform with biomarkers useful in emergency settings.

Sample: Patients over 18 years old presenting to the Emergency Department with mainly symptoms of cardiovascular conditions.

Trial Design: Prospective observational (cohort) feasibility study

Chief Investigator

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

Research Team

Caroline Blackstock

AMU Senior Research Nurse

Julia Grahamslaw

Lead Research Nurse

Rachel O'Brien

Lead Research Nurse

Fiona McCurrach

Senior Research Nurse

Alison Williams

Senior Research Nurse

Clare Moceivei

Research Nurse- Bank Staff

Nicky Freeman

Senior Research Nurse

Kayleigh Craig

Research Nurse

Fraser Craig

Clinical Trial Assistant

Claire Cheyne

Senior Research Nurse

More EMERGE Trials

Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.

Read more

IONA Study

Identification of Novel Psychoactive Substances (IONA)

People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.

Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.

KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.

Read more

KRAKIL Study

The RECOVERY Trial

Randomised Evaluation of COVID-19 Therapy